Celgene at buy by Merrill

Merrill Lynch analyst Tom McGahren rated Celgene Corp. at buy ahead of the company's earnings conference call. An initial look at the results shows strong sales of Revlimid and Thalomid and earnings per share of $0.15, higher than consensus and Merrill's estimate of $0.14. The analyst expects Celgene stock to move up on the news. Third-quarter Thalomid sales of $108 million were higher than the analyst's estimate of $106 million and consensus of $101 million. Shares of the Summit, N.J.-based pharmaceutical company were up $5.50, or 2.46%, at $49.64. (Nasdaq: CELG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.